Indaptus Therapeutics (INDP) Competitors $3.01 +0.05 (+1.69%) As of 12:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock INDP vs. PHXM, ALBT, IMCC, PCSA, VIVS, ADXN, APM, BCDA, RNAZ, and CELZShould you be buying Indaptus Therapeutics stock or one of its competitors? The main competitors of Indaptus Therapeutics include PHAXIAM Therapeutics (PHXM), Avalon GloboCare (ALBT), IM Cannabis (IMCC), Heatwurx (PCSA), VivoSim Labs (VIVS), Addex Therapeutics (ADXN), Aptorum Group (APM), BioCardia (BCDA), TransCode Therapeutics (RNAZ), and Creative Medical Technology (CELZ). These companies are all part of the "pharmaceutical products" industry. Indaptus Therapeutics vs. Its Competitors PHAXIAM Therapeutics Avalon GloboCare IM Cannabis Heatwurx VivoSim Labs Addex Therapeutics Aptorum Group BioCardia TransCode Therapeutics Creative Medical Technology Indaptus Therapeutics (NASDAQ:INDP) and PHAXIAM Therapeutics (NASDAQ:PHXM) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, profitability, media sentiment, institutional ownership and earnings. Which has more volatility and risk, INDP or PHXM? Indaptus Therapeutics has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500. Comparatively, PHAXIAM Therapeutics has a beta of 2.35, suggesting that its stock price is 135% more volatile than the S&P 500. Do institutionals & insiders have more ownership in INDP or PHXM? 7.1% of Indaptus Therapeutics shares are owned by institutional investors. Comparatively, 0.4% of PHAXIAM Therapeutics shares are owned by institutional investors. 20.8% of Indaptus Therapeutics shares are owned by insiders. Comparatively, 1.9% of PHAXIAM Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media refer more to INDP or PHXM? In the previous week, Indaptus Therapeutics had 1 more articles in the media than PHAXIAM Therapeutics. MarketBeat recorded 1 mentions for Indaptus Therapeutics and 0 mentions for PHAXIAM Therapeutics. Indaptus Therapeutics' average media sentiment score of 1.89 beat PHAXIAM Therapeutics' score of 0.00 indicating that Indaptus Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Indaptus Therapeutics Very Positive PHAXIAM Therapeutics Neutral Which has better valuation & earnings, INDP or PHXM? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIndaptus TherapeuticsN/AN/A-$15.02M-$37.66-0.08PHAXIAM TherapeuticsN/AN/A-$240KN/AN/A Do analysts prefer INDP or PHXM? Indaptus Therapeutics currently has a consensus target price of $238.00, indicating a potential upside of 7,806.98%. Given Indaptus Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Indaptus Therapeutics is more favorable than PHAXIAM Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indaptus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00PHAXIAM Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is INDP or PHXM more profitable? PHAXIAM Therapeutics' return on equity of 0.00% beat Indaptus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Indaptus TherapeuticsN/A -612.59% -243.78% PHAXIAM Therapeutics N/A N/A N/A SummaryIndaptus Therapeutics beats PHAXIAM Therapeutics on 7 of the 11 factors compared between the two stocks. Get Indaptus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for INDP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INDP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INDP vs. The Competition Export to ExcelMetricIndaptus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.34M$2.51B$5.65B$10.32BDividend YieldN/A56.32%5.68%4.61%P/E Ratio-0.0823.2775.6626.31Price / SalesN/A570.93521.00169.30Price / CashN/A174.1537.5661.52Price / Book0.285.1712.996.34Net Income-$15.02M$32.95M$3.29B$270.94M7 Day Performance17.12%0.77%-0.03%0.29%1 Month Performance-57.61%5.77%4.13%6.89%1 Year Performance-90.81%1.81%69.08%29.31% Indaptus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INDPIndaptus Therapeutics2.8891 of 5 stars$3.01+1.7%$238.00+7,807.0%-91.3%$3.34MN/A-0.086Positive NewsPHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049ALBTAvalon GloboCare0.7305 of 5 stars$2.70+3.8%N/A-23.3%$10.37M$1.33M-0.145Gap UpIMCCIM Cannabis0.7544 of 5 stars$1.96+1.6%N/A-22.3%$10.29M$39.44M-3.63340News CoveragePCSAHeatwurx3.7249 of 5 stars$0.20+0.0%$1.00+398.8%-84.3%$10.10MN/A-0.0920Positive NewsGap DownVIVSVivoSim Labs0.2881 of 5 stars$3.84-19.7%N/AN/A$9.98M$140K-0.3820Gap UpADXNAddex Therapeutics2.2913 of 5 stars$9.37-2.6%$30.00+220.2%-8.4%$9.93M$170.62K-27.5630Positive NewsUpcoming EarningsAPMAptorum Group0.9272 of 5 stars$1.85-5.6%N/A-12.8%$9.89MN/A0.0030BCDABioCardia3.4867 of 5 stars$1.70-20.9%$25.00+1,370.6%-38.6%$9.86MN/A-0.9240News CoveragePositive NewsAnalyst ForecastInsider TradeAnalyst RevisionGap DownHigh Trading VolumeRNAZTransCode Therapeutics2.3489 of 5 stars$11.67+6.6%$280.00+2,299.3%-99.9%$9.69MN/A0.009Gap DownCELZCreative Medical Technology1.7543 of 5 stars$3.71+6.6%N/A+0.6%$9.57M$10K-1.175 Related Companies and Tools Related Companies PHXM Alternatives ALBT Alternatives IMCC Alternatives PCSA Alternatives VIVS Alternatives ADXN Alternatives APM Alternatives BCDA Alternatives RNAZ Alternatives CELZ Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INDP) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Indaptus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Indaptus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
